Omeros (NASDAQ:OMER) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Omeros (NASDAQ:OMER) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.08, Zacks reports. During the same quarter in the prior year, the firm earned ($0.15) EPS.

Omeros Stock Down 4.1 %

Shares of OMER opened at $7.06 on Friday. The stock’s fifty day simple moving average is $8.56 and its 200-day simple moving average is $7.63. The firm has a market capitalization of $409.93 million, a PE ratio of -3.06 and a beta of 2.35. Omeros has a 12-month low of $2.97 and a 12-month high of $13.60.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Tuesday. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.